Benzinga Pro data, Yield10 Bioscience (NASDAQ:YTEN) reported Q1 sales of $149.00 thousand. Earnings fell to a loss of $3.33 million, resulting in a 11.78% decrease from last quarter. In Q4, Yield10 Bioscience brought in $152.00 thousand in sales but lost $2.98 million in earnings.

What Is Return On Capital Employed?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q1, Yield10 Bioscience posted an ROCE of -0.25%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

For Yield10 Bioscience, a negative ROCE ratio of -0.25% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Upcoming Earnings Estimate

Yield10 Bioscience reported Q1 earnings per share at $-0.68/share, which did not meet analyst predictions of $-0.65/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.